Press Release / Media Release

Panacea Biotec Limited is pleased to announce that its first-to-file ANDA of Prasugrel 5mg and 10mg tablets has been approved by the United States Food & Drug Administration (U.S.FDA). Under the provisions of Hatch-Waxman Act, the Company is entitled for 180-days of shared marketing exclusivity for Prasugrel HCL tablets with this final FDA approval

Pdf Link: Press Release / Media Release

Source : BSE -

Published on October 24, 2017


This article is closed for comments.
Please Email the Editor